Claims for Patent: 7,393,658

Summary for Patent: 7,393,658

Title:	Prion protein binding materials and methods of use
Abstract:	Prion protein binding materials and methods for using the binding materials to detect or remove a prion protein from a sample, such as a biological fluid or an environmental sample. The binding materials are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), recombinant prion protein (PrPr), and proteinase resistant prion protein (PrPres). Prions from various species, including humans and hamsters, are bound by the binding materials.
Inventor(s):	Carbonell; Ruben G. (Raleigh, NC), Shen; Honglue (Raleigh, NC), Gurgel; Patrick V. (Raleigh, NC), Wiltshire-Lyerly; Viteros (Raleigh, NC), Hammond; David J. (Laytonsville, MD), Burton; Steven J. (Little Eversden, GB)
Assignee:	Pathogen Removal and Diagnostic Technologies, Inc. (Wilmington, DE) North Carolina State University (Raleigh, NC)
Application Number:	10/817,117
Patent Claims:	1. A method of forming a complex between a prion protein and a prion protein binding material in a sample comprising contacting the sample with the prion protein binding material under conditions allowing formation of the complex between the prion protein and the prion protein binding material, wherein the prion protein binding material comprises a polymer matrix attached to a functional group, which polymer matrix comprises polymethacrylate, methacrylate, or a combination thereof and which functional group comprises a primary amine or trimethylaminoethyl group, and wherein the binding material binds specifically and selectively to the prion protein. 2. The method of claim 1, further comprising detecting the complex prior to a separation process from the sample, after a separation process from the sample, or both. 3. The method of claim 1, wherein the polymer matrix is in the form of (i) a porous, beaded methacrylate resin material derivatized with hydrophilic linear polymer chains; or (ii) a porous, beaded methacrylate resin material derivatized with hydroxylic functionalities, having the structure: ##STR00003## where R is a hydroxylated aliphatic group. 4. The method of claim 1, wherein the polymer matrix is a porous beaded methacrylate resin material derivatized with hydrophilic spacer chains terminating in a primary amino group, having the following chemical structure: ##STR00004## where the approximate ligand density is 100 .mu.mol/mL and HW-65 is the methacrylate bead comprising a mean particle size of 65 .mu.m and a mean pore size of 1000 .ANG.. 5. The method of claim 1 wherein the prion protein is PrPc, PrPsc, PrPr or PrPres. 6. The method of claim 1, wherein the prion binding material is in a chromatography column, on a membrane, fiber or bead, impregnated into a non-woven mesh or coating of a fiber, or contained within a filter housing, or a combination thereof. 7. The method of claim 1, wherein the sample is a biological sample, a food product, an environmental sample, or a water sample. 8. The method of claim 7, wherein the biological sample is derived from a human or an animal. 9. The method of claim 8, wherein the animal is a bovine, an ovine, a porcine, an equine, a murine or a Cervidae animal. 10. The method of claim 1 wherein the prion protein is a human, bovine, ovine, porcine, equine, murine, or a Cervidae animal prion protein. 11. The method of claim 7, wherein the biological sample is a blood-derived sample; a brain derived sample; a bodily fluid sample; a collagen extract; a gland extract; or a tissue homogenate or extract. 12. The method of claim 11, wherein the bodily fluid is blood, plasma, serum, cerebrospinal fluid, urine, saliva, milk, ductal fluid, tears, or semen. 13. The method of claim 11, wherein the blood-derived sample is a platelet concentrate, a plasma protein preparation, an immunoglobulin preparation, a plasma fractionation intermediate, an albumin preparation, a fibrinogen preparation, a factor XIII preparation, a thrombin preparation, a factor VIII preparation, avon Willebrand factor preparation, a protein C preparation, or an activated protein C preparation. 14. The method of claim 1, wherein the sample is a pharmaceutical composition, a therapeutic composition, a cosmetic composition, food, or a nutritional supplement. 15. The method of claim 7, wherein the biological sample is gelatin, jelly, milk or dairy product, collagen, or infant formula. 16. The method of claim 7, wherein the biological sample comprises serum albumin. 17. The method of claim 16, wherein the serum albumin is a human serum albumin or an animal serum albumin. 18. The method of claim 16, wherein the sample comprises up to approximately 50% serum albumin by weight. 19. The method of claim 1, wherein the sample comprises from approximately 5% to approximately 25% serum albumin by weight. 20. The method of claim 1, wherein the prion protein binding material further comprises a spacer connecting the polymer matrix and the functional group. 21. The method of claim 20, wherein the spacer is 20 atoms in length or less. 22. The method of claim 20, wherein the spacer is 5 to 10 atoms in length. 23. The method of claim 1, wherein the binding material comprises two or more binding materials having the same or different functional groups and the samples are contacted with the two or more binding materials simultaneously or in succession. 24. The method of claim 2, wherein the separation process comprises chromatography, solid support separation, membrane separation, reactor separation, magnetic separation, immunoseparation; colloidal separation, or a combination thereof. 25. The method of claim 1, wherein the binding material comprises a hydroxyl group. 26. The method of claim 1, wherein the binding material comprises a primary-amine containing hydroxylated methacrylate.

Details for Patent 7,393,658

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2023-04-04
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2023-04-04
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2023-04-04
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2023-04-04
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2023-04-04